$107.01
2.24% yesterday
Nasdaq, May 28, 10:17 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ

Jazz Pharmaceuticals Plc Stock price

$107.01
-5.88 5.21% 1M
-15.63 12.74% 6M
-16.14 13.11% YTD
+1.95 1.86% 1Y
-43.90 29.09% 3Y
-11.78 9.92% 5Y
-72.92 40.53% 10Y
Nasdaq, Closing price Wed, May 28 2025
-2.45 2.24%
ISIN
IE00B4Q5ZN47
Symbol
JAZZ
Sector
Industry

Key metrics

Market capitalization $6.75b
Enterprise Value $9.54b
P/E (TTM) P/E ratio 13.86
EV/FCF (TTM) EV/FCF 6.41
EV/Sales (TTM) EV/Sales 2.35
P/S ratio (TTM) P/S ratio 1.66
P/B ratio (TTM) P/B ratio 1.62
Revenue growth (TTM) Revenue growth 5.76%
Revenue (TTM) Revenue $4.06b
EBIT (operating result TTM) EBIT $594.53m
Free Cash Flow (TTM) Free Cash Flow $1.49b
Cash position $2.57b
EPS (TTM) EPS $7.90
P/E forward negative
P/S forward 1.60
EV/Sales forward 2.26
Short interest 10.00%
Show more

Is Jazz Pharmaceuticals Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.

Jazz Pharmaceuticals Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

Buy
90%
Hold
10%

Financial data from Jazz Pharmaceuticals Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4,065 4,065
6% 6%
100%
- Direct Costs 455 455
13% 13%
11%
3,610 3,610
5% 5%
89%
- Selling and Administrative Expenses 1,548 1,548
13% 13%
38%
- Research and Development Expense 842 842
5% 5%
21%
1,221 1,221
3% 3%
30%
- Depreciation and Amortization 626 626
2% 2%
15%
EBIT (Operating Income) EBIT 595 595
4% 4%
15%
Net Profit 482 482
46% 46%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Jazz Pharmaceuticals Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jazz Pharmaceuticals Plc Stock News

Neutral
PRNewsWire
7 days ago
DUBLIN , May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5, 2025 Fireside chat at 6:55 a.m. PDT / 9:55 a.m.
Neutral
Seeking Alpha
8 days ago
Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. The oxybate business experienced a setback when Avadel won the appeal that allows Lumryz to compete with Jazz's Xywav in idiopathic hypersomnia. There are three potential catalysts for the oncology business in the second half of the year that should translate to a revenue growth inflection poi...
Neutral
Seeking Alpha
22 days ago
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - President and Chief Operating Officer Rob Iannone - Executive Vice President, Global Head of R&D and Chief Medical Officer Phil Johnson - Chief Financial Offic...
More Jazz Pharmaceuticals Plc News

Company Profile

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Bruce Cozadd
Employees 2,800
Founded 2005
Website www.jazzpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today